Myelodysplastic Syndromes Treatment Market

Global Myelodysplastic Syndromes Treatment Market is valued at US$ 3.14 Billion in 2022 and expected to reach US$ 5.93 Billion by 2029 with a CAGR of 9.5% over the forecast period.

Global Myelodysplastic Syndromes Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2023-2029- Rising geriatric population and growing number of regulatory approvals of drugs for treating Myelodysplastic syndrome (MSD), are driving the growth of Global Myelodysplastic Syndromes Treatment Market.

Scope of Global Myelodysplastic Syndromes Treatment Market Report-

Myelodysplastic Syndrome (MDS) referred as a bone marrow failure disorder. It is a kind of bone marrow problem, wherein the bone marrow doesn't create sufficient healthy blood cells. These disorders are described by insufficient hematopoiesis, including irregularities for proliferation, differentiation, and apoptosis. This syndrome ordinarily influences the geriatric populace and is more frequently in more seasoned men than ladies. The various kinds of myelodysplastic syndromes are analyzed in light of specific changes in the platelets and bone marrow. Age and past therapy with chemotherapy or radiation treatment influence the risk of a myelodysplastic condition. Signs and side effects of a myelodysplastic condition incorporate windedness and feeling tired.

Tests that analyze the blood and bone marrow are utilized to analyze myelodysplastic syndromes. MD syndrome is characterized by unambiguous chromosomal mutations in the Janus Kinase gene, that incorporate cancellation of q arm in at least one chromosomes and complete the erasure of chromosome 5 or 7 and an additional copy of chromosome 8. MDS is diagnosed through a few strategies including blood count, peripheral blood smear test, cytochemistry, minuscule tests, immunotherapy, flow cytometry, cytogenetics, FISH, and PCR.

The Covid-19 pandemic had a negative impact on the global myelodysplastic syndromes (MDS) treatment market. The pandemic has disrupted healthcare systems globally, leading to challenges in the diagnosis, treatment, and management of MDS patients. Restrictions on non-essential medical services, reduced access to healthcare facilities, and diversion of resources to manage COVID-19 cases have affected the delivery of MDS treatments. Clinical trials and research activities have also been impacted. However, efforts are being made to ensure continuity of care through telemedicine, home-based treatments, and personalized treatment plans. The long-term impact on the MDS treatment market is still being assessed, and steps are being taken to mitigate the impact and support patients during these challenging times.

The global myelodysplastic syndromes treatment market is segmented on the basis of treatment type, end-user, and region & country level. Based on the treatment type, the global myelodysplastic syndromes treatment market is classified into chemotherapy, stem cell transplant, immune treatments and other. Based on the end-user, the global craniomaxillofacial devices market is classified into hospitals, homecare, specialty centers and other.

The regions covered in global myelodysplastic syndromes treatment market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global myelodysplastic syndromes treatment is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc.

Key Players for Global Myelodysplastic Syndromes Treatment Report-

Some major key players in the global myelodysplastic syndromes treatment market report cover prominent players like -

• Otsuka Pharmaceutical Co. Ltd.
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.
• Reddy's Laboratories Ltd.
• Cipla Limited
• Acceleron Pharma Inc.
• Onconova Therapeutics Inc.
• Aprea Therapeutics
• Geron
• Sun Pharmaceutical Industries Limited
• Mylan NV
• FibroGen Inc.
• other

Global Myelodysplastic Syndromes Treatment Market Segmentation:-

By Treatment Type:

• Chemotherapy
• Stem Cell Transplant
• Immune Treatments
• Other

By End-User:

• Hospitals
• Homecare
• Specialty Centers
• Other

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Rising Geriatric Population, Growing Regulatory Approval of Drugs for Treating Myelodysplastic Syndrome (MSD), Drive the Growth of Global Myelodysplastic Syndromes Treatment Market

One of the major factors driving the growth of the global myelodysplastic syndromes treatment market is the rising geriatric population. Most patients with myelodysplastic conditions (MDS) are old that is middle age range 65 to 70 years). As an outcome, the frequency and predominance of these diseases are ascending as the population ages. Hence, increasing number of older population drives the global myelodysplastic syndromes treatment market.

For example; according to the World Health Organization (WHO), by 2019, there were 254 million older individuals matured 60 and over, and 176 million older individuals matured 65 and over. By 2040, an expected 402 million individuals (28% of the absolute populace) will be beyond 60 years old.

In addition, growing number of regulatory approvals of drugs for treating myelodysplastic syndrome (MSD) is also supplementing the market growth. For instance; in February 2022, the U.S. Food and Drug Administration (FDA) approved Orphan drug assigned to Syros pharmaceuticals oral treatment, tamibarotene to treat myelodysplastic syndrome (MDS).

Furthermore, the increasing focus of government organizations and drug manufacturing companies spreading awareness about the myelodysplastic syndrome (MDS) disease also drive the global myelodysplastic syndromes treatment market. For instance; in July 2020, Takeda Pharmaceutical Company reported the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for its investigational drug pevonedistat for the therapy of patients with higher-risk myelodysplastic disorders (HR-MDS).

However, the high cost of myelodysplastic syndromes treatment may hamper the global myelodysplastic syndromes treatment market growth. In spite of that, rising research and development investments on the improvement of innovative treatments for MDS can provide various opportunities for the further growth of the global myelodysplastic syndromes treatment market over the forecast period.

North America is Expected to Dominate the Global Myelodysplastic Syndromes Treatment Market

North America is expected to dominate the global myelodysplastic syndromes treatment market due to the growing cases of MSD, rising research & development activities and presence of key players. Increasing cases of myelodysplastic syndromes increases the demand of myelodysplastic syndromes treatment over the forecast period.

For example; according to the American Cancer Society, there are about 60,000 people in the United States live with MDS, and over 13,000 new cases are reported every year. Increasing research & development activities also drive the global myelodysplastic syndromes treatment market development. For instance, in July 2020, the U.S. Food and Drug Administration (FDA) approved Inqovi (decitabine and cedazuridine) tablets for therapy of grown-up patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).

The Asia Pacific is anticipated to grow faster in the global myelodysplastic syndromes treatment market within the forecast period due to increasing geriatric population and developing healthcare infrastructure in the region. For example; according to the World Health Organization (WHO), by 2019, there were 254 million older individuals matured 60 and over, and 176 million older individuals matured 65 and over. By 2040, an expected 402 million individuals (28% of the absolute populace) will be beyond 60 years old. Hence, rising geriatric population in Asia Pacific region drives the myelodysplastic syndromes treatment market.

News-

I-Mab Announced Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

On September 10^th, 2022; I-Mab announced empowering data from its Stage 2 clinical preliminary (NCT04202003) of lemzoparlimab (otherwise called TJC4) in blend with azacitidine (AZA) in patients with recently diagnosed higher risk myelodysplastic disorder (HR-MDS), introduced in an oral presentation on September 10 at the European Society for Medical Oncology (ESMO) Congress 2022. The open-named Stage 2 clinical preliminary is intended to explore the safety and efficacy of lemzoparlimab in blend with AZA in patients with recently analyzed HR-MDS.

Novartis Received FDA Fast Track Designation for Sabatolimab (MBG453) In Myelodysplastic Syndromes

On May 25^th, 2021; Novartis announced that the U.S. Food and Drug Administration (FDA) granted fast track designation for sabatolimab (MBG453) for the treatment of adult patients with myelodysplastic syndromes (MDS) defined with an IPSS-R risk category of high or very high risk in combination with hypomethylating agents. Fast track designation facilitates the development and expedites the review of drugs to treat serious conditions and fill unmet medical needs.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2022:	USD 3.14 Billion
Base year considered	2021
Forecast Period CAGR %:	9.5%
Market Size Expected in 2029:	USD 5.93 Billion
Tables, Charts & Figures:	175
Pages	300
Key Players/Companies	Otsuka Pharmaceutical Co. Ltd., Celgene Corporation, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics Inc., Aprea Therapeutics, Geron, Sun Pharmaceutical Industries Limited, Mylan NV, FibroGen Inc., and other
Segments Covered	By Treatment Type, By End-User
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa